Atrium Health's Levine Cancer Institute - Charlotte (Main)

Atrium Health

Charlotte, NC

Sorting 15 by

Accepting patients

CARTITUDE-2

Phase 2, Open-Label Study Evaluating the Use of an Investigational CAR-T Cell therapy in Participants with Multiple Myeloma
Learn more
  • CAR T Cell
  • BCMA
  • Phase 2

Accepting patients

MonumenTAL-3

Phase 3 Clinical Trial Comparing the Efficacy of an Investigational Medication Combined with Daratumumab or Daratumumab and Pomalidomide Versus Daratumumab, Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma.
Learn more
  • Bispecific Antibody
  • GPRC5D
  • Randomization
  • Phase 3

Accepting patients

LINKER-MM3

A Trial to Learn How Well Linvoseltamab works Compared to the Combination of Elotuzumab, Pomalidomide and Dexamethasone for Adult Participants with Relapsed/Refractory Multiple Myeloma
Learn more
  • Bispecific Antibody
  • BCMA
  • Randomization
  • Phase 3

Accepting patients

KarMMa-2

Phase 2 Clinical Trial Studying the Safety and Efficacy of bb2121 in Participants with Relapsed and Refractory Multiple Myeloma or Clinical High-Risk Multiple Myeloma
Learn more
  • CAR T Cell
  • BCMA
  • High Risk
  • Phase 2
  • Has results

Accepting patients

DREAMM9

A Phase 1 Study of Belantamab Mafodotin Plus Standard of Care in Newly Diagnosed Multiple Myeloma
Learn more
  • Antibody Drug Conjugate (ADC)
  • BCMA
  • Randomization
  • Phase 1

Not currently accepting

DRAMMATIC

S1803, Lenalidomide +/- Daratumumab/rHuPh20 as Post-ASCT Maintenance for MM w/MRD to Direct Therapy Duration (DRAMMATIC)
Learn more
  • Monoclonal Antibody
  • CD38
  • Maintenance
  • Phase 3

Accepting patients

CARTITUDE-6

A Study of Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Ciltacabtagene Autoleucel Versus Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Autologous Stem Cell Transplant (ASCT) in Participants With Newly Diagnosed Multiple Myeloma (CARTITUDE-6)
Learn more
  • Autologous Stem Cell Transplant
  • CAR T Cell
  • BCMA
  • Phase 3

Accepting patients

LINKER-MM4

Phase 1/2 Study of Linvoseltamab (Anti-BCMA X Anti-CD3 Bispecific Antibody) in Previously Untreated Patients With Symptomatic Multiple Myeloma
Learn more
  • Bispecific Antibody
  • BCMA
  • Phase 1/2

Not yet accepting

MajesTEC-7

A Study to Compare Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) in Participants With Newly Diagnosed Multiple Myeloma (MajesTEC-7)
Learn more
  • Bispecific Antibody
  • BCMA
  • Randomization
  • Phase 3

Accepting patients

ABBV-383

A Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused ABBV-383 in Combination With Anti-Cancer Regimens for the Treatment of Adult Participants With Relapsed/Refractory Multiple Myeloma
Learn more
  • Bispecific Antibody
  • Gamma-Secretase Inhibitor
  • BCMA
  • Phase 1
1 hidden based on your filters. Show All